كليكسان

Nazione: Israele

Lingua: arabo

Fonte: Ministry of Health

Principio attivo:

ENOXAPARIN SODIUM 20 MG / 0.2 ML

Commercializzato da:

SANOFI - AVENTIS ISRAEL LTD

Codice ATC:

B01AB05

Forma farmaceutica:

SOLUTION FOR INJECTION

Via di somministrazione:

I.V, S.C

Prodotto da:

SANOFI WINTHROP INDUSTRIE, FRANCE

Gruppo terapeutico:

ENOXAPARIN

Indicazioni terapeutiche:

Enoxaparin sodium is an anti-coagulant. At dosesof 20 mg and 40 mg it is indicated for: - Prophylactic treatment of thrombo-embolic disorders of venous origin and in particular in orthopedic surgery or in general surgery. - Prevention of thrombus formation in the extra-corporeal circulation during hemodialysis. At dosege of 40 mg the indications are: - Prophylactic treatment of deep vein thrombosis in patients who are bedridden due to an acute medial disorder: - Heart failure (HYHA class III or IV) - Acute respiratory failure - Episode of acute infection or acute rheumatic disorder combined with at least one other venous thromboembolic risk factor. At high doses of 60, 80 ,100 mg Clexan is indicated for: -Treatment of deep vein thrombosis (DVT). - Treatment of unstable angina and non-Q-wave myocardial infaction administered concurrently with aspirin. - Treatment of pulmonary embolism.Treatment of acute ST- segment elevation myocardial infarction, in combination with a thrombolytic agent in patients eligible o

Data dell'autorizzazione:

2010-02-01